Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027

Showcased the versatility of its RedTail platform at the 2026 ASCO Annual Meeting with new CLD-501 data demonstrating the simultaneous in situ delivery of a TROP-2-targeted tumor-localized T-cell engager (TCE) alongside a T-cell amplifier; the Company is also advancing its EpCam-targeted in situ TCE program, representing an important advancement of the RedTail platform